Clozapine Treatment for Aggressive Behaviors in Youths with Neurodevelopmental Disorders
Journal of Child and Adolescent Psychopharmacology · 2024-04 · 34 (3) · 148-156
DOI: 10.1089/cap.2023.0097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Child and Adolescent Psychopharmacology, online erschienen am 11.04.2024. Verfasst von Stefano Berloffa und 8 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Stella Maris, Scientific Institute of Child Neurology and Psychiatry, Calambrone, Italy. Hauptthemen laut MEDLINE: Clozapine, Autism Spectrum Disorder, Neurodevelopmental Disorders, Antipsychotic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Objectives
The aim of this study was to assess effectiveness and tolerability of Clozapine in the treatment of aggression in youth with Neurodevelopmental Disorders.
Methods
Patients were consecutively admitted at our third-level university hospital with nationwide catchment from June 2018 to October 2022, and followed up to July 2023. Eligibility criteria were as follows: (1) Autism Spectrum Disorder (ASD) and/or Intellectual Disability/Borderline Cognitive Functioning, (2) behavioral dyscontrol with physical aggression; (3) age range between 8 and 18 years; (4) clinical indication for Clozapine treatment after at least two failed trials with other Second-Generation Antipsychotics (SGAs); (5) availability of an at least 6-month-long follow-up. To evaluate the response to Clozapine, we used the Clinical Global Impressions (CGI) rating scales (Clinical Global Impressions-Severity [CGI-S] and Clinical Global Impressions-Improvement [CGI-I]), the Children's Global Assessment Scale (CGAS), and the Aberrant Behavior Checklist (ABC).
Results
Twenty-six children and adolescents (21 boys, age 13.47 ± 2.05 years, follow-up duration 9.77 ± 3.50 months) were included in the analysis. Clinical severity (CGI-S) and functional impairment (Clinical Global Assessment Scale) significantly improved, as well as the ABC Total Score and the scores in several subscales. Sixteen patients (61.54%) were responders (CGI-I ≤2), and 13 (50.00%) displayed remission of aberrant behaviors (ΔABC-Total >35), while response/remission condition was not affected by add-on medications and psychotherapy. Most frequent side effects were increased appetite (50.00%), sialorrhea (38.46%), and increased repetitive behaviors (26.92%). Two patients presented epileptic seizures, while no patients presented leucopoenia.
Conclusions
Our results suggest that Clozapine may be helpful in ameliorating treatment-resistant aggression in youth with neurodevelopmental conditions. Possible pharmacological strategies for the management of most frequent side effects are also suggested.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IRCCS Stella Maris, Scientific Institute of Child Neurology and Psychiatry, Calambrone, Italy.
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
- Social and Affective Neuroscience Group, Molecular Mind Lab, IMT School for Advanced Studies Lucca, Lucca, Italy.
ORCID-Profile: Gianluca Sesso
Zitieren
APA
Berloffa, S., Masi, G., Falcone, F., Simonelli, V., Narzisi, A., Valente, E., Viglione, V., Milone, A., & Sesso, G. (2024). Clozapine Treatment for Aggressive Behaviors in Youths with Neurodevelopmental Disorders. Journal of Child and Adolescent Psychopharmacology, 34(3), 148-156. https://doi.org/10.1089/cap.2023.0097
Vancouver
Berloffa S, Masi G, Falcone F, Simonelli V, Narzisi A, Valente E, et al. Clozapine Treatment for Aggressive Behaviors in Youths with Neurodevelopmental Disorders. Journal of Child and Adolescent Psychopharmacology. 2024;34(3):148-156. doi:10.1089/cap.2023.0097
BibTeX
@article{Berloffa2024,
author = {Berloffa, Stefano and Masi, Gabriele and Falcone, Francesca and Simonelli, Valerio and Narzisi, Antonio and Valente, Elena and Viglione, Valentina and Milone, Annarita and Sesso, Gianluca},
title = {Clozapine Treatment for Aggressive Behaviors in Youths with Neurodevelopmental Disorders},
journal = {Journal of Child and Adolescent Psychopharmacology},
year = {2024},
volume = {34},
number = {3},
pages = {148--156},
doi = {10.1089/cap.2023.0097}
}
EUVIMED